Golub Group LLC Grows Position in Baxter International Inc (NYSE:BAX)

Golub Group LLC boosted its stake in shares of Baxter International Inc (NYSE:BAX) by 2.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 30,799 shares of the medical instruments supplier’s stock after purchasing an additional 876 shares during the period. Golub Group LLC’s holdings in Baxter International were worth $2,694,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in shares of Baxter International by 1.4% in the second quarter. BlackRock Inc. now owns 40,589,288 shares of the medical instruments supplier’s stock valued at $3,324,263,000 after acquiring an additional 560,814 shares in the last quarter. Morgan Stanley lifted its position in shares of Baxter International by 5.5% in the second quarter. Morgan Stanley now owns 17,154,303 shares of the medical instruments supplier’s stock valued at $1,404,937,000 after acquiring an additional 895,279 shares in the last quarter. Northern Trust Corp lifted its position in shares of Baxter International by 0.6% in the second quarter. Northern Trust Corp now owns 8,758,537 shares of the medical instruments supplier’s stock valued at $717,323,000 after acquiring an additional 54,889 shares in the last quarter. Veritas Asset Management LLP lifted its position in shares of Baxter International by 0.5% in the second quarter. Veritas Asset Management LLP now owns 7,886,549 shares of the medical instruments supplier’s stock valued at $645,908,000 after acquiring an additional 35,600 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec lifted its position in shares of Baxter International by 43.4% in the second quarter. Caisse DE Depot ET Placement DU Quebec now owns 6,430,469 shares of the medical instruments supplier’s stock valued at $526,655,000 after acquiring an additional 1,945,800 shares in the last quarter. Institutional investors own 83.45% of the company’s stock.

Shares of NYSE:BAX traded up $0.51 during mid-day trading on Friday, reaching $78.51. The stock had a trading volume of 3,017,392 shares, compared to its average volume of 2,768,937. The company has a current ratio of 2.78, a quick ratio of 2.10 and a debt-to-equity ratio of 0.72. The company has a market cap of $39.56 billion, a P/E ratio of 25.74, a price-to-earnings-growth ratio of 2.00 and a beta of 0.97. Baxter International Inc has a 1 year low of $61.40 and a 1 year high of $89.93. The business’s 50 day moving average price is $84.08 and its 200 day moving average price is $82.11.

In related news, SVP Andrew Frye sold 3,332 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $88.00, for a total value of $293,216.00. Following the sale, the senior vice president now directly owns 16,391 shares in the company, valued at $1,442,408. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Jacqueline Kunzler sold 5,934 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $88.12, for a total value of $522,904.08. Following the completion of the sale, the senior vice president now owns 3,089 shares in the company, valued at $272,202.68. The disclosure for this sale can be found here. Insiders sold 17,396 shares of company stock worth $1,528,575 over the last quarter. 0.70% of the stock is owned by company insiders.

Several equities analysts have recently commented on BAX shares. Royal Bank of Canada set a $87.00 price objective on Baxter International and gave the company a “hold” rating in a research report on Friday, July 26th. Wells Fargo & Co set a $95.00 price objective on Baxter International and gave the company a “buy” rating in a research report on Friday, July 26th. Deutsche Bank started coverage on Baxter International in a research report on Monday, October 21st. They issued a “buy” rating and a $109.00 price objective on the stock. Piper Jaffray Companies reiterated a “buy” rating on shares of Baxter International in a research report on Tuesday, September 10th. Finally, BMO Capital Markets boosted their target price on Baxter International to $95.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $90.14.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Recommended Story: Is it Safe to Invest in Commodities?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.